Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Ketorolac Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Ketorolac Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs quantity-limit coverage for 10 mg ketorolac tromethamine tablets under the Boeing commercial formulary. It establishes the standard dispensing limit and clinical criteria for approving quantities that exceed the limit.

    Policy Summary
    PayerPrime Therapeutics
    PolicyKetorolac Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 15, 2026
    Next Review DateN/A
    Key ActionFor quantities above the program limit, submit an applicable exception pathway and the supporting clinical rationale.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20 tabletsStandard quantity limit per prescription
    10 mgTarget tablet strength
    5 daysMaximum therapy duration
    12 monthsLength of approval

    Quantity-Limit Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Quantity-limit approval criteria

    Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:

    ONE of

    • Within program limit

      • The requested quantity (dose) does NOT exceed the program quantity limit.
    • ONE of the following exception pathways

      • No maximum FDA-labeled dose

        • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • Lower quantity of higher strength cannot achieve requested quantity

        • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.
        • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
      • Higher-than-labeled dose supported

        • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.

    Initial Therapy Approval

    Quantity-limit approval

    Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:

    ONE of

    • Within program limit

      • The requested quantity (dose) does NOT exceed the program quantity limit.
    • ONE of the following exception pathways

      • No maximum FDA-labeled dose

        • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • Lower quantity of higher strength cannot achieve requested quantity

        • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.
        • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
      • Higher-than-labeled dose supported

        • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.

    Exception Review and Documentation

    Prior Authorization

    Quantity-Limit Exception Review

    The requested quantity (dose) is approved when it does not exceed the program quantity limit. If the requested quantity exceeds the limit, additional exception review is required under one of the qualifying pathways below.

    • Standard approval: The requested quantity does not exceed the program quantity limit.
    • Above-limit request: The request must meet one of the qualifying exception pathways and include supporting clinical information.
    Documentation Required

    Supporting Clinical Rationale

    For a quantity above the program limit, submit clinical documentation supporting the requested dose and the applicable exception pathway. The documentation must establish one of the following: no maximum FDA-labeled dose exists for the indication and higher-dose therapy is supported; the requested dose is within the maximum FDA-labeled dose and cannot be achieved with a lower quantity of a higher-strength product that remains within the program limit; or the requested dose exceeds the maximum FDA-labeled dose and higher-dose therapy is supported.

    • The requested agent has no maximum FDA-labeled dose for the requested indication, with support for therapy at a higher dose.
    • The requested quantity does not exceed the maximum FDA-labeled dose, with support explaining why the dose cannot be achieved using a lower quantity of a higher strength that does not exceed the program quantity limit.
    • The requested quantity exceeds the maximum FDA-labeled dose, with support for therapy at the higher dose.
    • If approved, the length of approval is 12 months.
    Denial Risk

    Excess Quantity Without Qualifying Exception

    A quantity that exceeds the program limit will not be approved unless a qualifying exception applies and the required clinical support is provided. Requests lacking an applicable pathway or adequate documentation are subject to denial.

    • The requested quantity exceeds the program limit without support for a qualifying exception.
    • The request does not document the applicable FDA-labeled-dose circumstances or clinical rationale for the higher quantity.

    Policy Background

    The program applies a quantity limit of 20 tablets per prescription for oral ketorolac tromethamine 10 mg tablets. This limit follows product-labeling recommendations for no more than 5 days of therapy, with no more than 4 tablets per day.

    Standard Quantity Limit

    Quantity limits
    Medicationketorolac tromethamine tab.
    Strength10 mg
    Standard quantity limit20 tablets per prescription
    Day supply30 days
    Maximum therapy duration5 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyKetorolac Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 15, 2026
    Next Review DateN/A
    Key ActionFor quantities above the program limit, submit an applicable exception pathway and the supporting clinical rationale.
    SourceLink
    On This Page
    Quantity-Limit Coverage CriteriaInitial Therapy ApprovalException Review and DocumentationPolicy BackgroundStandard Quantity Limit